TL;DR: Aetna, a CVS Health company, modified CPB 1086 to establish coverage criteria for mitomycin intravesical solution (Zusduri), effective December 4, 2025. If your team bills CPT 51720 for bladder instillation in Aetna commercial plans, this coverage policy defines exactly when you'll get paid — and when you won't.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Mitomycin Intravesical Solution (Zusduri) |
| Policy Code | CPB 1086 |
| Change Type | Modified |
| Effective Date | December 4, 2025 |
| Impact Level | High |
| Specialties Affected | Urology, Oncology, Hematology-Oncology |
| Key Action | Submit precertification for Zusduri before administering — no exceptions for participating providers |
Aetna Mitomycin (Zusduri) Coverage Criteria and Medical Necessity Requirements 2025
The Aetna mitomycin intravesical coverage policy under CPB 1086 in the Aetna system is narrow by design. Aetna covers Zusduri for one indication: recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Everything else is experimental.
Medical necessity requires the patient to meet a specific clinical profile. The policy defines "intermediate-risk" using three markers — multiple tumors, a solitary tumor greater than 3 cm, and/or early or frequent recurrence. Your clinical documentation must support at least one of those markers to establish medical necessity. If the chart doesn't reflect the risk criteria, expect a claim denial.
Two structural requirements must also be met. First, Zusduri must be given via intravesical instillation — not systemic administration. Second, the protocol must be once weekly for six weeks, totaling six doses. Both conditions must appear in the treatment plan. If the administration route or dosing schedule deviates, Aetna will not consider it medically necessary under this policy.
Precertification is mandatory. Aetna participating providers have no workaround here. Call (866) 752-7021 or fax your prior authorization request to (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Don't assume the diagnosis alone carries the prior auth — Aetna needs the full clinical picture.
This policy covers commercial medical plans only. For Medicare patients, Aetna's Medicare Part B criteria apply separately. If your practice treats both populations, keep those workflows distinct.
Aetna Mitomycin (Zusduri) Exclusions and Non-Covered Indications
Aetna's position here is unusually clean: anything that isn't LG-IR-NMIBC is experimental, investigational, or unproven. Full stop.
That means muscle-invasive bladder cancer, high-grade NMIBC, carcinoma in situ used as a standalone indication (outside the LG-IR-NMIBC profile), and any off-label use of Zusduri won't pass medical necessity review. Don't submit those claims expecting reimbursement. You'll get a denial, and an appeal won't change the policy language.
D09.0 (carcinoma in situ of bladder) is listed in the policy's ICD-10 codes, which may create some confusion. Carcinoma in situ can coexist with LG-IR-NMIBC in a clinical picture, but D09.0 alone doesn't satisfy the coverage criteria. The documented indication must be LG-IR-NMIBC meeting the intermediate-risk markers. If your urologist is treating CIS independently with Zusduri, that claim will likely not survive review under this policy.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Recurrent low-grade intermediate-risk NMIBC (LG-IR-NMIBC) — multiple tumors, solitary tumor >3 cm, and/or early/frequent recurrence | Covered | CPT 51720; C67.0–C67.9 | Prior authorization required; intravesical instillation only; once weekly × 6 doses |
| Muscle-invasive bladder cancer | Not Covered / Experimental | C67.0–C67.9 | Not an approved indication under CPB 1086 |
| High-grade NMIBC | Not Covered / Experimental | C67.0–C67.9 | Falls outside LG-IR-NMIBC definition |
| Carcinoma in situ (standalone indication) | Not Covered / Experimental | D09.0 | CIS alone does not satisfy LG-IR-NMIBC criteria |
| Any other off-label use of Zusduri | Not Covered / Experimental | — | Aetna designates all other uses as investigational |
| Continuation of therapy (existing or new members) | Covered | CPT 51720; C67.0–C67.9 | Must re-meet all initial approval criteria at each authorization |
Aetna Mitomycin (Zusduri) Billing Guidelines and Action Items 2025
The effective date is December 4, 2025. If your practice administers Zusduri to Aetna commercial members, these steps apply now.
| # | Action Item |
|---|---|
| 1 | Verify precertification is in place before every Zusduri administration. Aetna requires it of all participating providers, no exceptions. Call (866) 752-7021 or fax (888) 267-3277. Missing this step on even one visit creates a clean claim denial that authorization alone can't fix after the fact. |
| 2 | Confirm the clinical documentation supports LG-IR-NMIBC with intermediate-risk markers. The chart must show at least one of: multiple tumors, a solitary tumor greater than 3 cm, or early/frequent recurrence. "Low-grade NMIBC" in the diagnosis alone isn't enough — Aetna's medical necessity criteria are more specific than the ICD-10 code. |
| 3 | Bill CPT 51720 for each intravesical instillation session. This is the procedure code for bladder instillation of an anticarcinogenic agent, including retention time. Pair it with the appropriate C67.x ICD-10 code reflecting the bladder tumor location. Use D09.0 only when carcinoma in situ is a documented comorbidity within the LG-IR-NMIBC clinical picture — not as a standalone primary diagnosis. |
| 4 | Document the administration route and dosing schedule in every encounter note. Intravesical instillation and once-weekly dosing for six weeks are structural requirements for medical necessity under CPB 1086. If your documentation doesn't confirm both, a post-payment audit will create reimbursement exposure. |
| 5 | Treat continuation therapy authorizations the same as initial authorizations. Aetna's continuation criteria simply require the member to re-meet all initial approval criteria. That means re-verifying the LG-IR-NMIBC diagnosis, risk markers, and administration parameters at each renewal. Don't treat continuation as automatic — re-document the clinical basis every time. |
| 6 | Separate your commercial and Medicare workflows for this drug. CPB 1086 covers Aetna commercial plans only. Aetna Medicare members follow Part B criteria, which are not defined in this bulletin. If your billing team treats those populations the same, you're creating both underpayment and overpayment risk. |
| 7 | If your patient volume for this drug is high, loop in your compliance officer. The combination of mandatory precertification, specific medical necessity criteria, and a narrow covered indication creates real audit exposure. A compliance review of your Zusduri billing guidelines before December 4, 2025 is time well spent. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Mitomycin Intravesical Solution Under CPB 1086
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 51720 | CPT | Bladder instillation of anticarcinogenic agent (including retention time) |
CPT 51720 is the procedure code for mitomycin intravesical billing under this policy. It covers the instillation itself and retention time in a single code. Don't unbundle — Aetna's coverage is built around this single CPT.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C67.0 | Malignant neoplasm of bladder |
| C67.1 | Malignant neoplasm of bladder |
| C67.2 | Malignant neoplasm of bladder |
| C67.3 | Malignant neoplasm of bladder |
| C67.4 | Malignant neoplasm of bladder |
| C67.5 | Malignant neoplasm of bladder |
| C67.6 | Malignant neoplasm of bladder |
| C67.7 | Malignant neoplasm of bladder |
| C67.8 | Malignant neoplasm of bladder |
| C67.9 | Malignant neoplasm of bladder |
| D09.0 | Carcinoma in situ of bladder |
One practical note on the C67.x codes: the policy lists all bladder site subclassifications (C67.0 through C67.9). Use the most specific code reflecting the documented tumor location in the pathology or operative report. C67.9 (unspecified) is a last resort — specificity supports medical necessity and reduces claim denial risk.
D09.0 is on the list because CIS can appear alongside LG-IR-NMIBC. But as noted above, it doesn't independently qualify a patient for Zusduri coverage under CPB 1086.
Get the Full Picture for CPT 51720
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.